CL2021001638A1 - Tratamiento del cáncer con docetaxel controlando los niveles plasmáticos máximos - Google Patents
Tratamiento del cáncer con docetaxel controlando los niveles plasmáticos máximosInfo
- Publication number
- CL2021001638A1 CL2021001638A1 CL2021001638A CL2021001638A CL2021001638A1 CL 2021001638 A1 CL2021001638 A1 CL 2021001638A1 CL 2021001638 A CL2021001638 A CL 2021001638A CL 2021001638 A CL2021001638 A CL 2021001638A CL 2021001638 A1 CL2021001638 A1 CL 2021001638A1
- Authority
- CL
- Chile
- Prior art keywords
- docetaxel
- cancer
- plasma levels
- peak plasma
- treatment
- Prior art date
Links
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title abstract 5
- 229960003668 docetaxel Drugs 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 230000036470 plasma concentration Effects 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 229940123237 Taxane Drugs 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18215472 | 2018-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001638A1 true CL2021001638A1 (es) | 2022-04-22 |
Family
ID=64901394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001638A CL2021001638A1 (es) | 2018-12-21 | 2021-06-18 | Tratamiento del cáncer con docetaxel controlando los niveles plasmáticos máximos |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20220079910A1 (enExample) |
| EP (2) | EP3897610B1 (enExample) |
| JP (3) | JP2022515249A (enExample) |
| KR (1) | KR20220002860A (enExample) |
| CN (1) | CN113543781A (enExample) |
| AU (2) | AU2019410060A1 (enExample) |
| BR (1) | BR112021012255A2 (enExample) |
| CA (1) | CA3124316C (enExample) |
| CL (1) | CL2021001638A1 (enExample) |
| ES (1) | ES3026709T3 (enExample) |
| IL (1) | IL284213A (enExample) |
| MX (2) | MX2021007478A (enExample) |
| PE (1) | PE20220250A1 (enExample) |
| WO (1) | WO2020127606A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3897610B1 (en) * | 2018-12-21 | 2025-04-16 | Modra Pharmaceuticals B.V. | Cancer treatment using docetaxel by controlling peak plasma levels |
| PE20220129A1 (es) * | 2018-12-21 | 2022-01-27 | Modra Pharmaceuticals B V | Tratamiento de combinacion para tumores solidos usando docetaxel y un inhibidor de cyp3a |
| GB202201935D0 (en) | 2022-02-14 | 2022-03-30 | Modra Pharmaceuticals B V | Methods and compositions for treating cancer in taxane-resistant patients |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR054215A1 (es) | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| KR101544498B1 (ko) * | 2007-08-24 | 2015-08-17 | 스티칭 허트 네덜란드 칸커 인스티튜트 | 종양성 질환의 치료를 위한 조성물 |
| US9089544B2 (en) * | 2007-08-24 | 2015-07-28 | Slotervaart Participaties Bv | Composition |
| WO2010020799A2 (en) | 2008-08-22 | 2010-02-25 | Slotervaart Participaties Bv | Composition |
| GB0716591D0 (en) * | 2007-08-24 | 2007-10-03 | Vereniging Het Nl Kanker I | Composition |
| EP3897610B1 (en) * | 2018-12-21 | 2025-04-16 | Modra Pharmaceuticals B.V. | Cancer treatment using docetaxel by controlling peak plasma levels |
| PE20220129A1 (es) * | 2018-12-21 | 2022-01-27 | Modra Pharmaceuticals B V | Tratamiento de combinacion para tumores solidos usando docetaxel y un inhibidor de cyp3a |
-
2019
- 2019-12-18 EP EP19828724.5A patent/EP3897610B1/en active Active
- 2019-12-18 WO PCT/EP2019/086124 patent/WO2020127606A1/en not_active Ceased
- 2019-12-18 CN CN201980090615.9A patent/CN113543781A/zh active Pending
- 2019-12-18 AU AU2019410060A patent/AU2019410060A1/en not_active Abandoned
- 2019-12-18 EP EP25169533.4A patent/EP4670718A3/en active Pending
- 2019-12-18 US US17/416,977 patent/US20220079910A1/en not_active Abandoned
- 2019-12-18 BR BR112021012255-9A patent/BR112021012255A2/pt not_active Application Discontinuation
- 2019-12-18 ES ES19828724T patent/ES3026709T3/es active Active
- 2019-12-18 CA CA3124316A patent/CA3124316C/en active Active
- 2019-12-18 JP JP2021536409A patent/JP2022515249A/ja active Pending
- 2019-12-18 KR KR1020217022968A patent/KR20220002860A/ko not_active Ceased
- 2019-12-18 PE PE2021001049A patent/PE20220250A1/es unknown
- 2019-12-18 MX MX2021007478A patent/MX2021007478A/es unknown
-
2021
- 2021-06-18 MX MX2025008270A patent/MX2025008270A/es unknown
- 2021-06-18 CL CL2021001638A patent/CL2021001638A1/es unknown
- 2021-06-20 IL IL284213A patent/IL284213A/en unknown
-
2022
- 2022-06-06 US US17/833,745 patent/US11571408B2/en active Active
-
2023
- 2023-05-01 JP JP2023075517A patent/JP2023102787A/ja active Pending
- 2023-07-14 AU AU2023204682A patent/AU2023204682A1/en not_active Abandoned
-
2025
- 2025-02-28 US US19/066,854 patent/US20250312305A1/en active Pending
- 2025-03-24 JP JP2025049089A patent/JP2025094189A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113543781A (zh) | 2021-10-22 |
| MX2025008270A (es) | 2025-08-01 |
| PE20220250A1 (es) | 2022-02-16 |
| EP3897610A1 (en) | 2021-10-27 |
| KR20220002860A (ko) | 2022-01-07 |
| IL284213A (en) | 2021-08-31 |
| US20220323399A1 (en) | 2022-10-13 |
| JP2025094189A (ja) | 2025-06-24 |
| EP3897610B1 (en) | 2025-04-16 |
| EP4670718A3 (en) | 2026-03-04 |
| US20220079910A1 (en) | 2022-03-17 |
| EP4670718A2 (en) | 2025-12-31 |
| JP2023102787A (ja) | 2023-07-25 |
| CA3124316A1 (en) | 2020-06-25 |
| EP3897610C0 (en) | 2025-04-16 |
| BR112021012255A2 (pt) | 2021-09-28 |
| JP2022515249A (ja) | 2022-02-17 |
| ES3026709T3 (en) | 2025-06-12 |
| US20250312305A1 (en) | 2025-10-09 |
| WO2020127606A1 (en) | 2020-06-25 |
| CA3124316C (en) | 2023-07-04 |
| MX2021007478A (es) | 2021-10-13 |
| US11571408B2 (en) | 2023-02-07 |
| AU2019410060A1 (en) | 2021-08-05 |
| AU2023204682A1 (en) | 2023-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000847A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| PE20191303A1 (es) | Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2 | |
| ES3063344T3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
| CO2020013968A2 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer | |
| WO2015184145A8 (en) | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer | |
| CL2017000080A1 (es) | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer | |
| MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
| AR102553A1 (es) | Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit | |
| MX2016016115A (es) | Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr). | |
| CL2017000317A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
| MX2015003643A (es) | Metodo para tratar el cancer. | |
| MX2019003134A (es) | Terapia de combinacion. | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| CL2023002549A1 (es) | Ciertos compuestos de pladienolida y métodos de uso (divisional). | |
| PH12018501451A1 (en) | Formulations for treating bladder cancer | |
| MX377118B (es) | C. novyi para el tratamiento de tumores solidos en humanos. | |
| MX2018007823A (es) | Terapia de combinacion de bromodominio e inhibidor de proteina extra terminal. | |
| MX2025008270A (es) | Uso prolongado de docetaxel en el tratamiento del cáncer. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2021003842A (es) | Terapia combinada para el tratamiento del cancer. | |
| CL2021001635A1 (es) | Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3a | |
| CO2021005797A2 (es) | Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia | |
| MX2018002681A (es) | Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1". | |
| MX2018015916A (es) | Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer. | |
| EP4706653A3 (en) | Therapeutic compositions comprising idelalisib and defactinib for treating breast cancers |